Publications by authors named "Helene Pillant"
Article Synopsis
- The study aimed to compare the effectiveness of surgical closure versus just seton removal for treating fistulizing perianal Crohn's disease in patients being treated with adalimumab.
- A randomized controlled trial involved 64 patients, where one group received surgical closure and seton removal, while the other group only had the seton removed.
- Results showed no significant difference in fistula closure rates between the two groups at 12 months, suggesting that seton removal alone may be just as effective as additional surgical intervention.
Background: Crohn's disease (CD)-associated dysbiosis could predispose patients to relapse. Gut microbiota composition of patients from the prospective cohort study designed to identify predictive factors of clinical relapse after infliximab discontinuation (STORI Study) was investigated to determine the impact of dysbiosis in CD relapse.
Methods: Fecal samples from 33 patients with CD in this cohort were collected at baseline, 2 months, 6 months, and at the end of the follow-up period (19 relapsers and 14 nonrelapsers).
Background & Aims: It is important to determine whether infliximab therapy can be safely interrupted in patients with Crohn's disease who have undergone a period of prolonged remission. We assessed the risk of relapse after infliximab therapy was discontinued in patients on combined maintenance therapy with antimetabolites and identified factors associated with relapse.
Methods: We performed a prospective study of 115 patients with Crohn's disease who were treated for at least 1 year with scheduled infliximab and an antimetabolite and had been in corticosteroid-free remission for at least 6 months.